At ESCAPE, we’re passionate about helping people suffering from inherited forms of neurodegeneration. Our pipeline includes candidates targeting known genetic drivers of multiple diseases. Our goal is to improve the lives of patients suffering from Alzheimer's disease, Parkinson's disease, and CNS lysosomal storage disorders.
Precision therapies targeting specific genetic populations have already come to market for other difficult-to-treat disease areas, such as cancer.
ESCAPE Bio Appoints Mark Kaufmann as Chief Financial Officer and Chief Business Officer
ESCAPE Bio to Present at Stifel’s 3rd Annual CNS Day
